Cited by 108Melanoma and MAPK PathwaysProtein Kinase Regulation and GTPase SignalingProtein Tyrosine Phosphatases

The DOI matches its Crossref record; 75 of the 75 references it cites were found in a registry or an index.

Cooperative interactions of PTEN deficiency and RAS activation in melanoma metastasis

Open access

Nogueira, C, Kim, K-H, Sung, H, Paraiso, K H T, Dannenberg, J-H, Bosenberg, M, Chin, L, Kim, M·2010·Oncogene

DOI 10.1038/onc.2010.349PMC PMC2989338

Open this paper in CoChat — free account

Abstract

Mitogen-activated protein kinase (MAPK) and AKT pathways are frequently co-activated in melanoma through overexpression of receptor tyrosine kinases, mutations in their signaling surrogates, such as RAS and BRAF, or loss of negative regulators such as PTEN. As RAS can be a positive upstream regulator of PI3-K, it has been proposed that the loss of PTEN and the activation of RAS are redundant events in melanoma pathogenesis. Here, in genetically engineered mouse models of cutaneous melanomas, we sought to better understand the genetic interactions between HRAS activation and PTEN inactivation in melanoma genesis and progression in vivo. We showed that HRAS activation cooperates with Pten+/- and Ink4a/Arf-/- to increase melanoma penetrance and promote metastasis. Correspondingly, gain- and loss-of-function studies established that Pten loss increases invasion and migration of melanoma cells and non-transformed melanocytes, and such biological activity correlates with a shift to phosphorylation of AKT2 isoform and E-cadherin down-regulation. Thus, Pten inactivation can drive the genesis and promote the metastatic progression of RAS activated Ink4a/Arf deficient melanomas.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Integrity signals

Registry

Crossref · 10.1038/onc.2010.349

Cites

75 of 75 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

1 retracted

AKT2 Inhibition of Cisplatin-induced JNK/p38 and Bax Activation by Phosphorylation of ASK1
Yuan, Z., Feldman, R. I., Sussman, G. E., Coppola, D., Nicosia, S. V., & Cheng, J. Q. (2003) · Journal of Biological Chemistry · doi:10.1074/jbc.m302674200 · Cited by 202
Retracted
Mutations of the BRAF gene in human cancer
Davies, H., Bignell, G. R., Cox, C., Stephens, P., Edkins, S., Clegg, S., Teague, J., Woffendin, H., Garnett, M. J., Bottomley, W., et al. (2002) · Nature · doi:10.1038/nature00766 · Cited by 10,674
PTEN , a Putative Protein Tyrosine Phosphatase Gene Mutated in Human Brain, Breast, and Prostate Cancer
Li, J., Yen, C., Liaw, D., Podsypanina, K., Bose, S., Wang, S. I., Puc, J., Miliaresis, C., Rodgers, L., McCombie, R., et al. (1997) · Science · doi:10.1126/science.275.5308.1943 · Cited by 4,785
A System for Stable Expression of Short Interfering RNAs in Mammalian Cells
Brummelkamp, T. R., Bernards, R., & Agami, R. (2002) · Science · doi:10.1126/science.1068999 · Cited by 4,295
Identification of a candidate tumour suppressor gene, MMAC1, at chromosome 10q23.3 that is mutated in multiple advanced cancers
Steck, P. A., Pershouse, M. A., Jasser, S. A., Yung, W. K. A., Lin, H., Ligon, A. H., Langford, L. A., Baumgard, M. L., Hattier, T., Davis, T., et al. (1997) · Nature Genetics · doi:10.1038/ng0497-356 · Cited by 2,742
High frequency of BRAF mutations in nevi
Pollock, P. M., Harper, U. L., Hansen, K. S., Yudt, L. M., Stark, M., Robbins, C. M., Moses, T. Y., Hostetter, G., Wagner, U., Kakareka, J., et al. (2003) · Nature Genetics · doi:10.1038/ng1054 · Cited by 1,730
Role of the INK4a Locus in Tumor Suppression and Cell Mortality
Serrano, M., Lee, H.-W., Chin, L., Cordon-Cardo, C., Beach, D., & DePinho, R. A. (1996) · Cell · doi:10.1016/s0092-8674(00)81079-x · Cited by 1,585
Self-citation
Pten is essential for embryonic development and tumour suppression
Cristofano, A. D., Pesce, B., Cordon‐Cardo, C., & Pandolfi, P. P. (1998) · Nature Genetics · doi:10.1038/1235 · Cited by 1,518
Beyond PTEN mutations: the PI3K pathway as an integrator of multiple inputs during tumorigenesis
Cully, M., You, H., Levine, A. J., & Mak, T. W. (2006) · Nature reviews. Cancer · doi:10.1038/nrc1819 · Cited by 1,267
BrafV600E cooperates with Pten loss to induce metastatic melanoma
Dankort, D., Curley, D. P., Cartlidge, R. A., Nelson, B., Karnezis, A. N., Damsky Jr, W. E., You, M. J., DePinho, R. A., McMahon, M., & Bosenberg, M. (2009) · Nature Genetics · doi:10.1038/ng.356 · Cited by 1,189
Self-citation

Show all 75 references

Sorted by citations

Exome sequencing identifies recurrent somatic RAC1 mutations in melanoma
Krauthammer, M., Kong, Y., Ha, B. H., Evans, P., Bacchiocchi, A., McCusker, J. P., Cheng, E., Davis, M. J., Goh, G., Choi, M., et al. (2012) · Nature Genetics · doi:10.1038/ng.2359 · Cited by 1,191
Self-citation
Lifetime Cancer Risks in Individuals with GermlinePTENMutations
Tan, M.-H., Mester, J. L., Ngeow, J. Y. Y., Rybicki, L. A., Orloff, M. S., & Eng, C. (2012) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-11-2283 · Cited by 892
Cutaneous melanoma: From pathogenesis to therapy (Review)
Leonardi, G. C., Falzone, L., Salemi, R., Zanghì, A., Spandidos, D. A., McCubrey, J. A., Candido, S., & Libra, M. (2018) · International Journal of Oncology · doi:10.3892/ijo.2018.4287 · Cited by 624
Signal pathways of melanoma and targeted therapy
Guo, W., Wang, H., & Li, C. (2021) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-021-00827-6 · Cited by 419
The metabolic landscape of RAS-driven cancers from biology to therapy
Mukhopadhyay, S., Vander Heiden, M. G., & McCormick, F. (2021) · Nature Cancer · doi:10.1038/s43018-021-00184-x · Cited by 315
The YUMM lines: a series of congenic mouse melanoma cell lines with defined genetic alterations
Meeth, K. M., Wang, J. X., Micevic, G., Damsky, W., & Bosenberg, M. (2016) · Pigment Cell & Melanoma Research · doi:10.1111/pcmr.12498 · Cited by 330
Self-citation
The Role of the PI3K-AKT Pathway in Melanoma
Davies, M. A. (2012) · The Cancer Journal · doi:10.1097/ppo.0b013e31824d448c · Cited by 240
Decoding Melanoma Metastasis
Damsky, W., Rosenbaum, L. E., & Bosenberg, M. (2010) · Cancers · doi:10.3390/cancers3010126 · Cited by 233
Self-citation
Directed migration of cancer cells guided by the graded texture of the underlying matrix
Park, J., Kim, D., Kim, H. N., Wang, C. J., Kwak, M. K., Hur, E., Suh, K. Y., An, S. S., & Levchenko, A. (2016) · Nature Materials · doi:10.1038/nmat4586 · Cited by 202
MiR-26a enhances metastasis potential of lung cancer cells via AKT pathway by targeting PTEN
Liu, B., Wu, X., Liu, B., Wang, C., Liu, Y., Zhou, Q., & Xu, K. (2012) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2012.07.019 · Cited by 184
RUNX2 and the PI3K/AKT axis reciprocal activation as a driving force for tumor progression
Cohen-Solal, K., Boregowda, R. K., & Lasfar, A. (2015) · Molecular Cancer · doi:10.1186/s12943-015-0404-3 · Cited by 170
Aetiology and Pathogenesis of Cutaneous Melanoma: Current Concepts and Advances
Strashilov, S. A., & Yordanov, A. D. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22126395 · Cited by 179
Melanoma metastasis: new concepts and evolving paradigms
Damsky, W., Theodosakis, N., & Bosenberg, M. (2013) · Oncogene · doi:10.1038/onc.2013.194 · Cited by 174
Self-citation
Genetic alterations of PTEN in human melanoma
Aguissa-Touré, A.-H., & Li, G. (2011) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-011-0878-0 · Cited by 170
AKT1 Activation Promotes Development of Melanoma Metastases
Cho, J. H., Robinson, J. P., Arave, R. A., Burnett, W. J., Kircher, D. A., Chen, G., Davies, M. A., Grossmann, A. H., VanBrocklin, M. W., McMahon, M., et al. (2015) · Cell Reports · doi:10.1016/j.celrep.2015.09.057 · Cited by 146
Recurrent hotspot mutations in HRAS Q61 and PI3K-AKT pathway genes as drivers of breast adenomyoepitheliomas
Geyer, F. C., Li, A., Papanastasiou, A. D., Smith, A. E., Selenica, P., Burke, K. A., Edelweiss, M., Wen, H., Piscuoglio, S., Schultheis, A. M., et al. (2018) · Nature Communications · doi:10.1038/s41467-018-04128-5 · Cited by 140
Cadherin switch from E- to N-cadherin in melanoma progression is regulated by the PI3K/PTEN pathway through Twist and Snail
Hao, L., Ha, J. R., Kuzel, P., Garcia, E., & Persad, S. (2012) · British Journal of Dermatology · doi:10.1111/j.1365-2133.2012.10824.x · Cited by 135
The Importance of Being PI3K in the RAS Signaling Network
Cuesta, C., Arévalo-Alameda, C., & Castellano, E. (2021) · Genes · doi:10.3390/genes12071094 · Cited by 125
PTEN regulation of ERK1/2 signaling in cancer
Chetram, M. A., & Hinton, C. V. (2012) · Journal of Receptors and Signal Transduction · doi:10.3109/10799893.2012.695798 · Cited by 114
PTEN functions as a melanoma tumor suppressor by promoting host immune response
Dong, Y., Richards, J.-A., Gupta, R., Aung, P. P., Emley, A., Kluger, Y., Dogra, S. K., Mahalingam, M., & Wajapeyee, N. (2014) · Oncogene · doi:10.1038/onc.2013.409 · Cited by 113
Targeting the Akt Kinase to Modulate Survival, Invasiveness and Drug Resistance of Cancer Cells
Cassinelli, G., Zuco, V., Gatti, L., Lanzi, C., Zaffaroni, N., Colombo, D., & Perego, P. (2013) · Current Medicinal Chemistry · doi:10.2174/09298673113209990106 · Cited by 104
Navigating the Therapeutic Complexity of PI3K Pathway Inhibition in Melanoma
Kwong, L. N., & Davies, M. A. (2013) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-13-0142 · Cited by 108
The Akt signaling pathway
Madhunapantula, S. V., Mosca, P. J., & Robertson, G. P. (2011) · Cancer Biology & Therapy · doi:10.4161/cbt.12.12.18442 · Cited by 96
Phytochemicals for the Management of Melanoma
Pal, H. C., Hunt, K. M., Diamond, A. C., Elmets, C. A., & Afaq, F. (2016) · Mini-Reviews in Medicinal Chemistry · doi:10.2174/1389557516666160211120157 · Cited by 89
Genetics of melanoma progression: the rise and fall of cell senescence
Bennett, D. C. (2015) · Pigment Cell & Melanoma Research · doi:10.1111/pcmr.12422 · Cited by 96
Melanoma: Molecular genetics, metastasis, targeted therapies, immunotherapies, and therapeutic resistance
Wagstaff, W., Mwamba, R. N., Grullon, K., Armstrong, M. L., Zhao, P., Hendren-Santiago, B. K., Qin, K. H., Li, A. J., Hu, D. A., Youssef, A., et al. (2022) · Genes & Diseases · doi:10.1016/j.gendis.2022.04.004 · Cited by 94
BRAF/MAPK and GSK3 signaling converges to control MITF nuclear export
Ngeow, K. C., Friedrichsen, H. J., Li, L., Zeng, Z., Andrews, S., Volpon, L., Brunsdon, H., Berridge, G., Picaud, S., Fischer, R., et al. (2018) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1810498115 · Cited by 89
Lipid metabolic Reprogramming: Role in Melanoma Progression and Therapeutic Perspectives
Pellerin, L., Carrié, L., Dufau, C., Nieto, L., Ségui, B., Levade, T., Riond, J., & Andrieu‐Abadie, N. (2020) · Cancers · doi:10.3390/cancers12113147 · Cited by 91
Cutaneous Melanoma: A Review of Multifactorial Pathogenesis, Immunohistochemistry, and Emerging Biomarkers for Early Detection and Management
Gosman, L. M., Țăpoi, D. A., & Costache, M. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms242115881 · Cited by 92
The Evolving Role of Radiation Therapy in the Management of Malignant Melanoma
Khan, N., Khan, M. K., Almasan, A., Singh, A. D., & Macklis, R. M. (2011) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/j.ijrobp.2010.12.071 · Cited by 71
Differential AKT dependency displayed by mouse models of BRAFV600E-initiated melanoma
Durban, V. M., Deuker, M. M., Bosenberg, M., Phillips, W. A., & McMahon, M. (2013) · Journal of Clinical Investigation · doi:10.1172/jci69619 · Cited by 74
Self-citation
AKT1E17K Activates Focal Adhesion Kinase and Promotes Melanoma Brain Metastasis
Kircher, D. A., Trombetti, K. A., Silvis, M. R., Parkman, G. L., Fischer, G. M., Angel, S. N., Stehn, C. M., Strain, S. C., Grossmann, A. H., Duffy, K. L., et al. (2019) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-18-1372 · Cited by 70
WNT/β-catenin signaling regulates mitochondrial activity to alter the oncogenic potential of melanoma in a PTEN-dependent manner
Brown, K., Yang, P., Salvador, D., Kulikauskas, R. M., Ruohola‐Baker, H., Robitaille, A. M., Chien, A. J., Moon, R. T., & Sherwood, V. (2017) · Oncogene · doi:10.1038/onc.2016.450 · Cited by 67
The transcription factor ATF2 promotes melanoma metastasis by suppressing protein fucosylation
Lau, E. K., Feng, Y., Claps, G., Fukuda, M. N., Perlina, A., Donn, D., Jilaveanu, L. B., Kluger, H. M., Freeze, H. H., & Ronai, Z. A. (2015) · Science Signaling · doi:10.1126/scisignal.aac6479 · Cited by 62
Melanoma therapeutics: a literature review
Dhanyamraju, P. K., & Patel, T. (2022) · Journal of Biomedical Research · doi:10.7555/jbr.36.20210163 · Cited by 65
Future of radiation therapy for malignant melanoma in an era of newer, more effective biological agents
Khan, M. K., & Almasan, A. (2011) · OncoTargets and Therapy · doi:10.2147/ott.s20257 · Cited by 66
Glutamatergic signaling in cellular transformation
Teh, J. L. F., & Chen, S. (2012) · Pigment Cell & Melanoma Research · doi:10.1111/j.1755-148x.2012.00983.x · Cited by 59
Combined analysis of KRAS and PIK3CA mutations, MET and PTEN expression in primary tumors and corresponding metastases in colorectal cancer
Voutsina, A., Tzardi, M. N., Kalikaki, A., Zafeiriou, Z., Papadimitraki, E., Papadakis, M., Mavroudis, D., & Georgoulias, V. (2012) · Modern Pathology · doi:10.1038/modpathol.2012.150 · Cited by 55
A Tumor Suppressor Function for the Lipid Phosphatase INPP4B in Melanocytic Neoplasms
Pérez‐Lorenzo, R., Gill, K. Z., Shen, C., Zhao, F., Zheng, B., Schulze, H.-J., Silvers, D. N., Brunner, G., & Horst, B. A. J. (2013) · Journal of Investigative Dermatology · doi:10.1038/jid.2013.511 · Cited by 55
Chemotherapy-Induced Depletion of OCT4-Positive Cancer Stem Cells in a Mouse Model of Malignant Testicular Cancer
Pierpont, T. M., Lyndaker, A. M., Anderson, C. M., Jin, Q., Moore, E. S., Roden, J., Braxton, A. M., Bagepalli, L., Kataria, N., Hu, H. Z., et al. (2017) · Cell Reports · doi:10.1016/j.celrep.2017.10.078 · Cited by 55
Born to be Alive: A Role for the BCL-2 Family in Melanoma Tumor Cell Survival, Apoptosis, and Treatment
Anvekar, R. A., Asciolla, J. J., Missert, D. J., & Chipuk, J. E. (2011) · Frontiers in Oncology · doi:10.3389/fonc.2011.00034 · Cited by 57
N-cadherin regulates mammary tumor cell migration through Akt3 suppression
Chung, S., Yao, J., Suyama, K., Bajaj, S., Qian, X., Loudig, O. D., Eugenín, E. A., Phillips, G. R., & Hazan, R. B. (2012) · Oncogene · doi:10.1038/onc.2012.65 · Cited by 54
Ceramide Kinase Inhibition Drives Ferroptosis and Sensitivity to Cisplatin in Mutant KRAS Lung Cancer by Dysregulating VDAC-Mediated Mitochondria Function
Vu, N., Kim, M., Stephenson, D., MacKnight, H. P., & Chalfant, C. E. (2022) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-22-0085 · Cited by 53
Self-citation
Targeting sphingosine kinase‐1 to inhibit melanoma
Madhunapantula, S. V., Hengst, J. A., Gowda, R., Fox, T. E., Yun, J. K., & Robertson, G. P. (2012) · Pigment Cell & Melanoma Research · doi:10.1111/j.1755-148x.2012.00970.x · Cited by 52
Therapeutic Implications of Targeting AKT Signaling in Melanoma
Madhunapantula, S. V., & Robertson, G. P. (2011) · Enzyme Research · doi:10.4061/2011/327923 · Cited by 57
Modelling melanoma in mice
Walker, G. J., Soyer, H. P., Terzian, T., & Box, N. F. (2011) · Pigment Cell & Melanoma Research · doi:10.1111/j.1755-148x.2011.00923.x · Cited by 49
A Phosphatidylinositol 3-Kinase–Pax3 Axis Regulates Brn-2 Expression in Melanoma
Bonvin, E., Falletta, P., Shaw, H. M., Delmas, V., & Goding, C. R. (2012) · Molecular and Cellular Biology · doi:10.1128/mcb.01067-12 · Cited by 48
MicroRNA-28 promotes cell proliferation and invasion in gastric cancer via the PTEN/PI3K/AKT signalling pathway
Li, L., Zhu, X., Shou, T., Yang, L., Cheng, X., Wang, J., Deng, L., & Zheng, Y. (2017) · Molecular Medicine Reports · doi:10.3892/mmr.2017.8299 · Cited by 48
Current understanding of epigenetics role in melanoma treatment and resistance
Fath, M. K., Azargoonjahromi, A., Soofi, A., Almasi, F., Hosseinzadeh, S., Khalili, S., Sheikhi, K., Ferdousmakan, S., Owrangi, S., Fahimi, M., et al. (2022) · Cancer Cell International · doi:10.1186/s12935-022-02738-0 · Cited by 51
Active β-catenin is regulated by the PTEN/PI3 kinase pathway: a role for protein phosphatase PP2A
Persad, A. R. L., Venkateswaran, G., Li, H., Garcia, M. E., Yoon, J., Sidhu, J., & Persad, S. (2017) · Genes & Cancer · doi:10.18632/genesandcancer.128 · Cited by 45
Downregulation of MicroRNA-147 Inhibits Cell Proliferation and Increases the Chemosensitivity of Gastric Cancer Cells to 5-Fluorouracil by Directly Targeting PTEN
Shen, J., Niu, W., Zhang, H., Jun, M., & Zhang, H. (2017) · Oncology Research Featuring Preclinical and Clinical Cancer Therapeutics · doi:10.3727/096504017x15061902533715 · Cited by 44
Retracted
Functional Effects of GRM1 Suppression in Human Melanoma Cells
Wangari-Talbot, J., Wall, B., Goydos, J. S., & Chen, S. (2012) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-12-0158 · Cited by 46
Multifaceted Regulation of PTEN Subcellular Distributions and Biological Functions
Liu, T., Wang, Y., Wang, Y., & Chan, A. M.-L. (2019) · Cancers · doi:10.3390/cancers11091247 · Cited by 41
High-expression of DJ-1 and Loss of PTEN Associated with Tumor Metastasis and Correlated with Poor Prognosis of Gastric Carcinoma
Li, Y., Cui, J., Zhang, C., Yang, D., Chen, J., Zhan, W.-H., Li, B., Li, Z., & He, Y. (2013) · International Journal of Medical Sciences · doi:10.7150/ijms.7292 · Cited by 40
PTEN and Melanomagenesis
Conde‐Perez, A., & Larue, L. (2012) · Future Oncology · doi:10.2217/fon.12.106 · Cited by 41
Advances in melanoma senescence and potential clinical application
Giuliano, S., Ohanna, M., Ballotti, R., & Bertolotto, C. (2010) · Pigment Cell & Melanoma Research · doi:10.1111/j.1755-148x.2010.00820.x · Cited by 39
Metabotropic glutamate receptors and cancerous growth
Teh, J. L. F., & Chen, S. (2011) · Wiley Interdisciplinary Reviews Membrane Transport and Signalling · doi:10.1002/wmts.21 · Cited by 33
Genetics of melanoma
Wangari‐Talbot, J., & Chen, S. (2013) · Frontiers in Genetics · doi:10.3389/fgene.2012.00330 · Cited by 34
Defining the Tumor Microenvironment by Integration of Immunohistochemistry and Extracellular Matrix Targeted Imaging Mass Spectrometry
Rujchanarong, D., Lefler, J. E., Saunders, J. E., Pippin, S., Spruill, L., Bethard, J. R., Ball, L. E., Mehta, A. S., Drake, R. R., Ostrowski, M. C., et al. (2021) · Cancers · doi:10.3390/cancers13174419 · Cited by 32
Animal models of melanoma: a somatic cell gene delivery mouse model allows rapid evaluation of genes implicated in human melanoma
McKinney, A. J., & Holmen, S. L. (2011) · 癌症：英文版 · doi:10.5732/cjc.011.10007 · Cited by 31
Non-pungent long chain capsaicin-analogs arvanil and olvanil display better anti-invasive activity than capsaicin in human small cell lung cancers
Hurley, J. D., Akers, A. T., Friedman, J. R., Nolan, N. A., Brown, K. C., & Dasgupta, P. (2016) · Cell Adhesion & Migration · doi:10.1080/19336918.2016.1187368 · Cited by 31
The transcription factor RUNX2 regulates receptor tyrosine kinase expression in melanoma
Boregowda, R. K., Medina, D. J., Markert, E. K., Bryan, M. A., Chen, W., Chen, S., Rabkin, A., Vido, M. J., Gunderson, S., Chekmareva, M. A., et al. (2016) · Oncotarget · doi:10.18632/oncotarget.8822 · Cited by 31
A majority of human melanoma cell lines exhibits an S phase-specific defect in excision of UV-induced DNA photoproducts
Bélanger, F., Rajotte, V., & Drobetsky, E. A. (2014) · PLoS ONE · doi:10.1371/journal.pone.0085294 · Cited by 29
Mouse melanoma models and cell lines
Damsky, W., & Bosenberg, M. (2010) · Pigment Cell & Melanoma Research · doi:10.1111/j.1755-148x.2010.00777.x · Cited by 28
Self-citation
Targeting protein kinase-b3 (akt3) signaling in melanoma
Madhunapantula, S. V., & Robertson, G. P. (2017) · Expert Opinion on Therapeutic Targets · doi:10.1080/14728222.2017.1279147 · Cited by 25
TBX2 controls a proproliferative gene expression program in melanomaPreprint
Lu, S., Louphrasitthiphol, P., Goradia, N., Lambert, J., Schmidt, J., Chauhan, J. S., Rughani, M. G., Larue, L., Wilmanns, M., & Goding, C. R. (2021) · Genes & Development · doi:10.1101/gad.348746.121 · Cited by 21
Chromosome 10, Frequently Lost in Human Melanoma, Encodes Multiple Tumor-Suppressive Functions
Kwong, L. N., & Chin, L. (2014) · Cancer Research · doi:10.1158/0008-5472.can-13-1446 · Cited by 22
Self-citation
Human relevance of NRAS/BRAF mouse melanoma models
Conde‐Perez, A., & Larue, L. (2013) · European Journal of Cell Biology · doi:10.1016/j.ejcb.2013.10.010 · Cited by 22
The Role of Senescent Cells in Acquired Drug Resistance and Secondary Cancer in BRAFi-Treated Melanoma
Thompson, E. L., Hu, J., & Niedernhofer, L. J. (2021) · Cancers · doi:10.3390/cancers13092241 · Cited by 19
Microrna-136 promotes proliferation and invasion ingastric cancer cells through Pten/Akt/P-Akt signaling pathway
Chen, X., Huang, Z., & Chen, R. (2018) · Oncology Letters · doi:10.3892/ol.2018.7848 · Cited by 20
Obesity and melanoma: Exploring molecular links
Chen, J., Chi, M., Chen, C., & Zhang, X. D. (2013) · Journal of Cellular Biochemistry · doi:10.1002/jcb.24549 · Cited by 20
Activating PIK3CA mutations coexist with BRAF or NRAS mutations in a limited fraction of melanomas
Manca, A., Lissia, A., Capone, M., Ascierto, P. A., Botti, G., Caracò, C., Stanganelli, I., Colombino, M., Sini, M. C., Cossu, A., et al. (2015) · Journal of Translational Medicine · doi:10.1186/s12967-015-0401-8 · Cited by 18
Metabotropic glutamate receptor 1 mediates melanocyte transformation via transactivation of insulin‐like growth factor 1 receptor
Teh, J. L. F., Shah, R., Shin, S., Wen, Y., Mehnert, J. M., Goydos, J. S., & Chen, S. (2014) · Pigment Cell & Melanoma Research · doi:10.1111/pcmr.12237 · Cited by 16
Glutamatergic Signaling a Therapeutic Vulnerability in Melanoma
Eddy, K., & Chen, S. (2021) · Cancers · doi:10.3390/cancers13153874 · Cited by 15
PLEKHA5: A Key to Unlock the Blood–Brain Barrier?
Eisele, S. C., Gill, C. M., Shankar, G. M., & Brastianos, P. K. (2015) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-14-2604 · Cited by 14
Cooperative interactions of PTEN deficiency and RAS activation in melanoma metastasis
Kim, M. (2010) · Small GTPases · doi:10.4161/sgtp.1.3.14344 · Cited by 14
Self-citation
Cooperative function of oncogenic MAPK signaling and the loss of Pten for melanoma migration through the formation of lamellipodia
Yasuta, Y., Kaminaka, R., Nagai, S., Mouri, S., Ishida, K., Tanaka, A., Zhou, Y., Sakurai, H., & Yokoyama, S. (2024) · Scientific Reports · doi:10.1038/s41598-024-52020-8 · Cited by 12
Current Management of Malignant Melanoma: State of the Art
Kutlubay, Z., Engіn, B., Serdaroğlu, S., & Tuzu, Y. (2013) · InTech eBooks · doi:10.5772/55304 · Cited by 9
The PI3K-AKT Pathway in Melanoma
Siroy, A. E., Davies, M. A., & Lazar, A. J. (2016) · Springer eBooks · doi:10.1007/978-1-4939-3554-3_7 · Cited by 8
Molecular Biology and Genetic Mechanisms in the Progression of the Malignant Skin Melanoma
Pejkova, S., Dzokic, G., Tudzarova-Gjorgova, S., & Панов, С. (2016) · PRILOZI · doi:10.1515/prilozi-2016-0021 · Cited by 8
AKT2 Loss Impairs BRAF-Mutant Melanoma Metastasis
McRee, S. K., Bayer, A. L., Pietruska, J. R., Tsichlis, P. N., & Hinds, P. W. (2023) · Cancers · doi:10.3390/cancers15204958 · Cited by 8
The Roles of PTEN in Melanoma Suppression
Parkman, G. L., Xu, X., Holmen, S. L., & Karreth, F. A. (2025) · Pigment Cell & Melanoma Research · doi:10.1111/pcmr.70054 · Cited by 7
Taking stock of translational research in melanoma at the 2010 Society for Melanoma Research Congress
Flaherty, K. T. (2010) · Pigment Cell & Melanoma Research · doi:10.1111/j.1755-148x.2010.00816.x · Cited by 7
Combination of chemotherapy with BRAF inhibitors results in effective eradication of malignant melanoma by preventing ATM-dependent DNA repair
Alonso‐Marañón, J., Villanueva, A., Piulats, J. M., Martínez‐Iniesta, M., Solé, L., Martín-Liberal, J., Segura, S., Pujol, R. M., Iglesias, M., Bigas, A., et al. (2021) · Oncogene · doi:10.1038/s41388-021-01879-2 · Cited by 7
Refining mutanome-based individualised immunotherapy of melanoma using artificial intelligence
Zakariya, F., Salem, F. K., Alamrain, A. A., Sanker, V., Abdelazeem, Z. G., Hosameldin, M., Tan, J. K., Howard, R., Huang, H. Y. R., & Awuah, W. A. (2024) · European journal of medical research · doi:10.1186/s40001-023-01625-2 · Cited by 6
An Experimental Protocol for the Boyden Chamber Invasion Assay With Absorbance Readout
Brown, K. C., Sugrue, A. M., Modi, K. J., Light, R. S., Conley, K. B., Cox, A. J., Bender, C. R., Miles, S. L., Valentovic, M. A., & Dasgupta, P. (2024) · BIO-PROTOCOL · doi:10.21769/bioprotoc.5040 · Cited by 5
Cancer stem cells, plasticity, and drug resistance
Lionetti, M. C., Fumagalli, M. R., & Porta, C. A. M. L. (2020) · Cancer Drug Resistance · doi:10.20517/cdr.2019.112 · Cited by 6
Skin, Hair, and Nails
Sundberg, J. P., King, L. E., & Kuiper, R. (2021) · Wiley eBooks · doi:10.1002/9781119624608.ch10 · Cited by 4
Federated SPARQL query performance evaluation for exploring disease model mouse: combining gene expression, orthology, and disease knowledge graphs
Kushida, T., de Farias, T. M., Sima, A. C., Dessimoz, C., Chiba, H., Bastian, F., & Masuya, H. (2025) · BMC Medical Informatics and Decision Making · doi:10.1186/s12911-025-03013-8 · Cited by 2
Pathophysiology roles and translational opportunities of miRNAs in cutaneous melanoma
Ferracin, M., Broseghini, E., & Dika, E. (2022) · Elsevier eBooks · doi:10.1016/b978-0-12-822287-4.00022-0 · Cited by 2
Exploring Disease Model Mouse Using Knowledge Graphs: Combining Gene Expression, Orthology, and Disease DatasetsPreprint
Kushida, T., de Farias, T. M., Sima, A. C., Dessimoz, C., Chiba, H., Bastian, F., & Masuya, H. (2023) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2023.08.30.555283 · Cited by 2
Actionable Mutation Profile of Sun-Protected Melanomas in South America
Hsieh, R., Nico, M. M. S., Coutinho‐Camillo, C. M., Oliveira, K. K., Carraro, D. M., Sangüeza, M., & Lourenço, S. V. (2022) · American Journal of Dermatopathology · doi:10.1097/dad.0000000000002213 · Cited by 1
Understanding Melanocyte Transformation – A Work in Progress
Wangari‐Talbot, J., Goydos, J. S., & Che, S. (2011) · InTech eBooks · doi:10.5772/19753 · Cited by 1
Impact of circRNA on the complex regulatory network of the cell
Porta, C. A. M. L. (2019) · Non-coding RNA Investigation · doi:10.21037/ncri.2019.05.01 · Cited by 1
Signaling Networks that Induce Melanomagenesis and Metastasis that can be Exploited for Therapeutic Benefit
Tanzosh, E. E. (2013)
Role of checkpoint kinase 1 in malignant melanoma
Smith, J. (2013) · Enlighten: Theses (The University of Glasgow)
Skin Diseases-Related Enzymes: Mechanisms and Clinical Applications
Park, Y., Yang, J., & Lü, Z.-R. (2011) · Enzyme Research · doi:10.4061/2011/464507
New Approaches to Signaling
Sullivan, R. J., & Flaherty, K. T. (2017) · Springer eBooks · doi:10.1007/978-3-319-41319-8_16
Parallel and Serial Blockade Strategies in BRAF-Mutant Melanoma
Davies, M. A. (2014) · Cancer drug discovery and develogment/Cancer drug discovery and development · doi:10.1007/978-1-4939-2143-0_6
Regulation of ERK1/2 signaling in melanoma
Haydn, J. M. (2012)

Authors: Nogueira, C., Kim, K.-H., Sung, H., Paraiso, K. H. T., Dannenberg, J.-H., Bosenberg, M., Chin, L., & Kim, M.
Affiliations: Dana-Farber Cancer Institute (US)
Moffitt Cancer Center (US)
University of Vermont (US)
Harvard University (US)
Corresponding author: Chin, L
Kim, M
ORCID: Nogueira, C
Bosenberg, M
Kim, M
Venue: Oncogene
Publisher: Springer Science and Business Media LLC
Published: 2010-08-16
Volume: 29
Issue: 47
Pages: 6222-6232
ISSN: 0950-9232 (ISSN-L)
1476-5594
DOI: 10.1038/onc.2010.349
PMC: PMC2989338
OpenAlex: W2147690515
Cited by: 108
References: 75
Citations by year: 2026: 1 · 2025: 2 · 2024: 3 · 2023: 4 · 2022: 6 · 2021: 10 · 2020: 2 · 2019: 3 · 2018: 6 · 2017: 7 · 2016: 8 · 2015: 6 · 2014: 4 · 2013: 15 · 2012: 14
FWCI: 6.00
Type: journal article
Language: en
Open access: green
www.ncbi.nlm.nih.gov
Licence: www.springer.com/tdm (tdm)
www.springer.com/tdm (vor)
Locations: Oncogene (publishedVersion)
PubMed Central (publishedVersion)
PubMed (publishedVersion)
Europe PMC (PubMed Central) (acceptedVersion)
PubMed Central (acceptedVersion)
Funders: National Cancer Institute (R01CA93947, R01CA093947, U01CA084313, UO1 CA84313)
Topics: Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Melanoma and MAPK Pathways
Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Protein Kinase Regulation and GTPase Signaling
Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Protein Tyrosine Phosphatases
Keywords: melanoma, PTEN loss, Ras activation, HRAS, CDKN2A, Ink4a/Arf, melanoma metastasis, genetic interactions, PI3K/Akt signaling, E-cadherin, epithelial-mesenchymal transition, tumor cell migration and invasion, Akt2 phosphorylation, RNA interference
MeSH terms: Animals, Cell Transformation, Neoplastic, Enzyme Activation, Humans, Isoenzymes, Melanocytes, Melanoma, Neoplasm Invasiveness, Neoplasm Metastasis, Down-Regulation, Cadherins, Proto-Oncogene Proteins p21(ras), Cell Line, Tumor, Proto-Oncogene Proteins c-akt, PTEN Phosphohydrolase, Mice, Gene Knockdown Techniques

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Cooperative interactions of PTEN deficiency and RAS activation in melanoma metastasis

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Self-check

Citations

Cites

Cited by

Related

Metadata

Record

About these checks